RNAi therapeutics · Rare genetic diseases · Biotechnology
Alnylam Pharmaceuticals
A biotech developing RNA interference (RNAi) therapies for rare genetic diseases. NASDAQ 100 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
ALNY Updated Jul 11, 2026 5 AI consumers· 3 recurring
Annual return · 2026-09-04'21+30.5%'22+40.1%'23-19.5%'24+22.9%'25+69%YTD-33.1%
Money in ▸·
Alnylam Pharmaceuticals~$2.25B
▸ Money out·
Financials & Segments
- Total revenue · ~$2.25B (FY2024)
- Segments · RNAi Product Sales · Collaboration & Royalties
Revenue from
No refined links yet.
Pays to
No refined links yet.